NCT02445612View on ClinicalTrials.gov

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

CompletedOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

July 11, 2012

Primary Completion Date

June 21, 2019

Study Completion Date

June 21, 2019

Conditions
Stargardt's Macular Dystrophy
Interventions
BIOLOGICAL

MA09-hRPE

Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells

Trial Locations (3)

19107

Wills Eye Institute-Mid Atlantic Retina, Philadelphia

33136

Bascom Palmer Eye Institute, Miami

90095

Jules Stein Eye Institute, UCLA School of Medicine, Los Angeles

All Listed Sponsors
lead

Astellas Institute for Regenerative Medicine

INDUSTRY

NCT02445612 - Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients | Biotech Hunter | Biotech Hunter